Information Provided By:
Fly News Breaks for May 7, 2019
May 7, 2019 | 06:25 EDT
JPMorgan analyst Cory Kasimov raised his price target for GW Pharmaceuticals to $215 from $180 saying he's not sure how the company's Q1 results could have gone much better with Epidiolex doubling consensus estimates in its first full quarter of sales. He believes Epidiolex is on track to come in north of $150M in its first full year of sales. Estimates need to come up, says Kasimov, who keeps an Overweight rating on shares of GW Pharmaceuticals.
News For GWPH From the Last 2 Days
There are no results for your query GWPH